Resectable Sinonasal Mucosal Melanoma in the Immunotherapy Era: Upfront Surgery vs. Neoadjuvant Therapy

被引：2

作者：

Salem, Aya F. ^{[1
]}

Chen, Melissa M. ^{[2
]}

Williams, Michelle D. ^{[3
]}

Swanson, David M. ^{[4
]}

Mcquade, Jennifer L. ^{[5
]}

Amaria, Rodabe N. ^{[5
]}

Hanna, Ehab Y. ^{[6
]}

Bishop, Andrew J. ^{[1
]}

Farooqi, Ahsan S. ^{[1
]}

Guadagnolo, B. Ashleigh ^{[1
]}

Su, Shirley Y. ^{[6
]}

Mitra, Devarati ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Neuroradiol Dept, Houston, TX USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Anat Pathol, Houston, TX USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX USA

[5] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX USA

[6] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX USA

来源：

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2025年 / 47卷 / 07期

关键词：

immune checkpoint inhibition; neoadjuvant immunotherapy; sinonasal melanoma; STAGE-III MELANOMA; NASAL CAVITY; IPILIMUMAB; ADJUVANT; NIVOLUMAB; HEAD;

D O I：

10.1002/hed.28098

中图分类号：

R76 [耳鼻咽喉科学];

学科分类号：

100213 ;

摘要：

ObjectiveWe aim to evaluate outcomes for patients with resectable SNMM treated in the immunotherapy era.MethodsThirty-seven patients with resectable SNM were identified using our institutional database between 2016 and 2023.ResultsPatients receiving neoadjuvant Ipi/Nivo (46%, n = 17) were more likely to have disease involving the sinuses and/or the skull base (71% vs. 35%, p = 0.05). The overall response rate to Ipi/Nivo was 24%. Two-year LRFS from the start of therapy was 63%, and from the end of local therapy was 78%. Two-year PFS was 49%. The patients who received Ipi/Nivo with evidence of response (n = 4, 24%) had better PFS (2-year PFS 100% vs. 15%, p = 0.02) and LRFS (2-year LRFS 100% vs. 31%, p = 0.08).ConclusionsOutcomes for resectable SNMM patients continue to be poor in the immunotherapy era. In the context of selection bias, neoadjuvant Ipi/Nivo was not associated with better outcomes in all-comers. However, those with evidence of response to Ipi/Nivo had better prognosis.

引用

页码：1848 / 1856

页数：9

共 33 条

[1] Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma [J].

Amaria, Rodabe N. ;

Reddy, Sangeetha M. ;

Tawbi, Hussein A. ;

Davies, Michael A. ;

Ross, Merrick, I ;

Glitza, Isabella C. ;

Cormier, Janice N. ;

Lewis, Carol ;

Hwu, Wen-Jen ;

Hanna, Ehab ;

Diab, Adi ;

Wong, Michael K. ;

Royal, Richard ;

Gross, Neil ;

Weber, Randal ;

Lai, Stephen Y. ;

Ehlers, Richard ;

Blando, Jorge ;

Milton, Denai R. ;

Woodman, Scott ;

Kageyama, Robin ;

Wells, Daniel K. ;

Hwu, Patrick ;

Patel, Sapna P. ;

Lucci, Anthony ;

Hessel, Amy ;

Lee, Jeffrey E. ;

Gershenwald, Jeffrey ;

Simpson, Lauren ;

Burton, Elizabeth M. ;

Posada, Liberty ;

Haydu, Lauren ;

Wang, Linghua ;

Zhang, Shaojun ;

Lazar, Alexanderj ;

Hudgens, Courtney W. ;

Gopalakrishnan, Vancheswaran ;

Reuben, Alexandre ;

Andrews, Miles C. ;

Spencer, Christine N. ;

Prieto, Victor ;

Sharma, Padmanee ;

Allison, James ;

Tetzlaff, Michael T. ;

Wargo, Jennifer A. .

NATURE MEDICINE, 2018, 24 (11) :1649-+

[2] Approaches to Regional Lymph Node Metastasis in Patients With Head and Neck Mucosal Melanoma [J].

Amit, Moran ;

Tam, Samantha ;

Abdelmeguid, Ahmed S. ;

Roberts, Dianna B. ;

Raza, Shaan M. ;

Su, Shirley Y. ;

Kupferman, Michael E. ;

DeMonte, Franco ;

Hanna, Ehab Y. .

CANCER, 2018, 124 (03) :514-520

[3] Role of Adjuvant Treatment in Sinonasal Mucosal Melanoma [J].

Amit, Moran ;

Tam, Samantha ;

Abdelmeguid, Ahmed S. ;

Kupferman, Michael E. ;

Su, Shirley Y. ;

Raza, Shaan M. ;

DeMonte, Franco ;

Hanna, Ehab Y. .

JOURNAL OF NEUROLOGICAL SURGERY PART B-SKULL BASE, 2017, 78 (06) :512-518

[4] Sinonasal mucosal melanoma: treatment strategies and survival rates for a rare disease entity A single center experience and review of literature [J].

Andrianakis, Alexandros ;

Kiss, Peter ;

Pomberger, Markus ;

Wolf, Axel ;

Thurnher, Dietmar ;

Tomazic, Peter Valentin .

WIENER KLINISCHE WOCHENSCHRIFT, 2021, 133 (21-22) :1137-1147

[5] Postoperative Radiotherapy in Head and Neck Mucosal Melanoma A GETTEC Study [J].

Benlyazid, Adil ;

Thariat, Juliette ;

Temam, Stephane ;

Malard, Olivier ;

Florescu, Carmen ;

Choussy, Olivier ;

Makeieff, Marc ;

Poissonnet, Gilles ;

Penel, Nicolas ;

Righini, Christian ;

Toussaint, Bruno ;

St Guily, Jean Lacau ;

Vergez, Sebastien ;

Filleron, Thomas .

ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2010, 136 (12) :1219-1225

[6] Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis [J].

D'Angelo, Sandra P. ;

Larkin, James ;

Sosman, Jeffrey A. ;

Lebbe, Celeste ;

Brady, Benjamin ;

Neyns, Bart ;

Schmidt, Henrik ;

Hassel, Jessica C. ;

Hodi, F. Stephen ;

Lorigan, Paul ;

Savage, Kerry J. ;

Miller, Wilson H., Jr. ;

Mohr, Peter ;

Marquez-Rodas, Ivan ;

Charles, Julie ;

Kaatz, Martin ;

Sznol, Mario ;

Weber, Jeffrey S. ;

Shoushtari, Alexander N. ;

Ruisi, Mary ;

Jiang, Joel ;

Wolchok, Jedd D. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (02) :226-+

[7] Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study [J].

Dimitriou, F. ;

Namikawa, K. ;

Reijers, I. L. M. ;

Buchbinder, E., I ;

Soon, J. A. ;

Zaremba, A. ;

Teterycz, P. ;

Mooradian, M. J. ;

Armstrong, E. ;

Nakamura, Y. ;

Vitale, M. G. ;

Tran, L. E. ;

Bai, X. ;

Allayous, C. ;

Provent-Roy, S. ;

Indini, A. ;

Bhave, P. ;

Farid, M. ;

Kahler, K. C. ;

Mehmi, I ;

Atkinson, V ;

Klein, O. ;

Stonesifer, C. J. ;

Zaman, F. ;

Haydon, A. ;

Carvajal, R. D. ;

Hamid, O. ;

Dummer, R. ;

Hauschild, A. ;

Carlino, M. S. ;

Mandala, M. ;

Robert, C. ;

Lebbe, C. ;

Guo, J. ;

Johnson, D. B. ;

Ascierto, P. A. ;

Shoushtari, A. N. ;

Sullivan, R. J. ;

Cybulska-Stopa, B. ;

Rutkowski, P. ;

Zimmer, L. ;

Sandhu, S. ;

Blank, C. U. ;

Lo, S. N. ;

Menzies, A. M. ;

Long, G., V .

ANNALS OF ONCOLOGY, 2022, 33 (09) :968-980

[8] Pattern and prognostic value of lymph node metastasis in sinonasal mucosal melanoma [J].

Ding, Weiquan ;

Xie, Liangen ;

Liang, Jiangang ;

Li, Zhihui ;

Hu, Tingbao ;

Chen, Xiaohua ;

Zhang, Tao ;

Liu, Tianrun .

ENT-EAR NOSE & THROAT JOURNAL, 2022, :NP278-NP286

[9] Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial [J].

Eggermont, Alexander M. M. ;

Chiarion-Sileni, Vanna ;

Grob, Jean-Jacques ;

Dummer, Reinhard ;

Wolchok, Jedd D. ;

Schmidt, Henrik ;

Hamid, Omid ;

Robert, Caroline ;

Ascierto, Paolo A. ;

Richards, Jon M. ;

Lebbe, Celeste ;

Ferraresi, Virginia ;

Smylie, Michael ;

Weber, Jeffrey S. ;

Maio, Michele ;

Konto, Cyril ;

Hoos, Axel ;

de Pril, Veerle ;

Gurunath, Ravichandra Karra ;

de Schaetzen, Gaetan ;

Suciu, Stefan ;

Testori, Alessandro .

LANCET ONCOLOGY, 2015, 16 (05) :522-530

[10] Demographics and Treatment Trends in Sinonasal Mucosal Melanoma [J].

Gal, Thomas J. ;

Silver, Natalie ;

Huang, Bin .

LARYNGOSCOPE, 2011, 121 (09) :2026-2033

← 1 2 3 4 →